Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct:53:33-41.
doi: 10.1016/j.breast.2020.05.013. Epub 2020 Jun 4.

Mammographic density changes during neoadjuvant breast cancer treatment: NeoDense, a prospective study in Sweden

Ida Skarping  1 , Daniel Förnvik  2 , Uffe Heide-Jørgensen  3 , Hanna Sartor  4 , Per Hall  5 , Sophia Zackrisson  6 , Signe Borgquist  7
Affiliations

Mammographic density changes during neoadjuvant breast cancer treatment: NeoDense, a prospective study in Sweden

Ida Skarping et al. Breast. 2020 Oct.

Abstract

Objectives: To assess if mammographic density (MD) changes during neoadjuvant breast cancer treatment and is predictive of a pathological complete response (pCR).

Methods: We prospectively included 200 breast cancer patients assigned to neoadjuvant chemotherapy (NACT) in the NeoDense study (2014-2019). Raw data mammograms were used to assess MD with a fully automated volumetric method and radiologists categorized MD using the Breast Imaging-Reporting and Data System (BI-RADS), 5th Edition. Logistic regression was used to calculate odds ratios (OR) for pCR comparing BI-RADS categories c vs. a, b, and d as well as with a 0.5% change in percent dense volume adjusting for baseline characteristics.

Results: The overall median age was 53.1 years, and 48% of study participants were premenopausal pre-NACT. A total of 23% (N = 45) of the patients accomplished pCR following NACT. Patients with very dense breasts (BI-RADS d) were more likely to have a positive axillary lymph node status at diagnosis: 89% of the patients with very dense breasts compared to 72% in the entire cohort. A total of 74% of patients decreased their absolute dense volume during NACT. The likelihood of accomplishing pCR following NACT was independent of volumetric MD at diagnosis and change in volumetric MD during treatment. No trend was observed between decreasing density according to BI-RADS and the likelihood of accomplishing pCR following NACT.

Conclusions: The majority of patients decreased their MD during NACT. We found no evidence of MD as a predictive marker of pCR in the neoadjuvant setting.

Keywords: Breast cancer; Breast density; Mammography; Neoadjuvant therapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest SZ and HS have received speakers’ fees and travel support from Siemens Healthcare AG. SZ has received consultancy fees from Collective Minds Radiology AB. PH is a member of a scientific advisory board for: Cancer Research UK, iCAD and Atossa Genetics. SB has received speakers’ fees from Pfizer, is a member of a Pfizer advisory board, and has received travel support from Roche. The other authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Patient flow chart.
Fig. 2
Fig. 2
Study timeline.
Fig. 3
Fig. 3
Agreement between BI-RADS and volumetric breast density percentage (VBD%bilat).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McCormack V.A., dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev. 2006;15(6):1159–1169. - PubMed
    1. Li J., Humphreys K., Eriksson L., Edgren G., Czene K., Hall P. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer. J Clin Oncol. 2013;31(18):2249–2256. - PMC - PubMed
    1. Shawky M.S., Martin H., Hugo H.J., Lloyd T., Britt K.L., Redfern A., Thompson E.W. Mammographic density: a potential monitoring biomarker for adjuvant and preventative breast cancer endocrine therapies. Oncotarget. 2017;8(3):5578–5591. - PMC - PubMed
    1. Sickles E., D’Orsi C.J., Bassett L.W. ACR BI-RADS® Atlas, breast imaging reporting and data system. American College of Radiology; Reston, VA: 2013. ACR BI-RADS® mammography.
    1. Gubern-Merida A., Kallenberg M., Platel B., Mann R.M., Marti R., Karssemeijer N. Volumetric breast density estimation from full-field digital mammograms: a validation study. PloS One. 2014;9(1) - PMC - PubMed

MeSH terms